Formulations:
- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
Indications:
- Acute myeloid leukaemia with recurrent genetic abnormalities
- Lymphoid leukaemia, not elsewhere classified
- Myeloid leukaemia
Source: EML workbook import
Product metadata will be available once the catalog entry is complete.
Formulations:
- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)
Indications:
- Acute myeloid leukaemia with recurrent genetic abnormalities
- Lymphoid leukaemia, not elsewhere classified
- Myeloid leukaemia
Source: EML workbook import